Our findings suggest that administration of vasoprotective agents (for example, a S1PR2 antagonist) at the time of reperfusion could be a novel strategy to diminish cerebrovascular complications of reperfusion injury, ultimately resulting in less neurovascular injury and improved stroke outcomes52, 53, 54 (Fig. 9). This evidence concerns the gene S1PR2 and Stroke.